GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of the Analyst/Investor Meeting18-02-2021
18-02-2021
Granules India gets USFDA nod for its Potassium Chloride ER Capsules USP
Granules India Limited has announced that the US Food & Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Potassium17-02-2021
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Granules India Limited announces approval of Potassium Chloride ER Capsules USP, generic equivalent of Micro-K ER Capsules of Nesher Pharmaceuticals (USA) LLC17-02-2021
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of the Analyst/Investor Meeting11-02-2021
Buy Granules India; target of Rs 460: ICICI Direct
ICICI Direct is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 460 in its research report dated January 29, 2021.04-02-2021
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of the Analyst/Investor Meeting04-02-2021
Buy Granules India; target of Rs 460: Motilal Oswal
Motilal Oswal is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 460 in its research report dated January 28, 2021.03-02-2021
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Granules India Limited announces approval of Potassium Chloride Oral Solution USP, generic equivalent of Potassium Chloride Oral Solution of Genus Lifesciences, Inc.01-02-2021
Granules Q3 net profit more than doubles to 147 cr
Granules India Ltd's consolidated net profit more than doubled at 147 crore in the third quarter ended December 31, 2020 against 64 crore in the co29-01-2021
Earnings Call for Q3FY21 of Granules India
Conference Call with Granules India Management and Analysts on Q3FY21 Performance and Outlook. Listen to the full earnings transcript.29-01-2021